Indore facility OAI classification
Indore facility received OAI from US FDA; corrective measures are ongoing but may delay US approvals.
high · management_commentaryCipla Ltd — Q2 FY24
Cipla delivered a record quarter with revenue of ₹6,678 crore (+15% YoY) and EBITDA margin of 26%, driven by double-digit growth across India (+10%), North America (+28% to $229...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Albuterol market share volatility
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
medium · analyst_questionRevlimid volume uncertainty post-12-month period
Analyst questioned Revlimid volume trajectory after the initial 12-month period; management gave no specific guidance.
medium · analyst_question